← Eichor
Condition: Relapsed Refractory Peripheral T Cell Lymphoma R R Ptcl Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Relapsed Refractory Peripheral T Cell Lymphoma R R Ptcl

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Zeprumetostat, Azacitidine Combined With Lipo-MIT in R/R PTCL
Phase 2 · 1 location(s) · The First Affiliated Hospital of Soochow University · NCT07372352Chidamide and Duvalisibon for the Treatment of Refractory/Relapsed Peripheral T-cell Lymphoma
Phase 2 · 1 location(s) · The First Affiliated Hospital of Xiamen University · NCT06151106A Phase I/II Study of Golidocitinib Combined with Pomalidomide in R/R PTCL
Phase 1/Phase 2 · 1 location(s) · Sun Yat-sen University · NCT06855823Chidamide in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (R/R PTCL)
Phase 2 · 6 location(s) · Great Novel Therapeutics Biotech & Medicals Corporation · NCT05833724CD7 CAR T-Cell Therapy for r/r T-cell Lymphomas
Phase 1/Phase 2 · 4 location(s) · Beijing GoBroad Hospital · NCT06925464CD5 CAR T-Cell Therapy for r/r T-cell Lymphomas
Phase 1/Phase 2 · 3 location(s) · Beijing GoBroad Hospital · NCT07022964To Observe the CD7-targeted CAR-T Therapy in the Treatment of r/r PTCL
Phase 1 · 1 location(s) · Peking University People's Hospital · NCT07143929Nanobody-Based Anti-CD5 CAR-T for Relapsed/Refractory T-ALL/NHL
Phase 1/Phase 2 · 1 location(s) · Peking University People's Hospital · NCT06874946A Phase 3 Multinational Study of Golidocitinib Versus Investigator's Choice in r/r PTCL (JACKPOT19)
Phase 3 · 51 location(s) · Dizal Pharmaceuticals · NCT07234162A Platform Trial Evaluating New Drugs or Combination in R/R Peripheral T-cell Lymphomas
Phase 1/Phase 2 · 20 location(s) · The Lymphoma Academic Research Organisation · NCT07018752Study to Evaluate Efficacy and Safety of HH2853 in Relapsed/Refractory Peripheral T-cell Lymphoma
Phase 1/Phase 2 · 1 location(s) · Haihe Biopharma Co., Ltd. · NCT06909877
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.